Antihyperglycemic Effect of Ginkgo biloba Extract in Streptozotocin-Induced Diabetes in Rats
Table 3
Effect of GBE treatment on hepatic and pancreatic oxidative stress markers of rats in experimental groups.
N group
D group
N + G group
D + LG group
D + MG group
D + HG group
D + GLI group
Liver
GSH (μg/mg protein)
512.36 ± 91.25
365.50 ± 84.77a
529.36 ± 101.23b
400.28 ± 79.46
451.33 ± 89.44c
486.36 ± 98.31b
482.09 ± 106.30c
CAT (U/mg protein)
362.63 ± 18.52
302.05 ± 22.82a
374.47 ± 26.36b
313.25 ± 24.47
322.52 ± 17.52c
349.96 ± 25.01b
344.80 ± 20.91b
SOD (U/mg protein)
542.35 ± 24.21
235.27 ± 34.22a
602.0 ± 40.50b
322.21 ± 32.65b
414.11 ± 35.33b
505.20 ± 41.52b
523.36 ± 36.66b
GSH-Px (U/mg protein)
3023 ± 217
2236 ± 259a
3111 ± 285b
2567 ± 198b
2758 ± 252b
2904 ± 220b
2808 ± 244b
MDA (nmol/mg protein)
9.03 ± 1.25
16.91 ± 1.81a
8.85 ± 1.33b
14.28 ± 1.57b
10.05 ± 1.01b
9.66 ± 1.41b
10.36 ± 1.55b
Pancreas
GSH (μg/mg protein)
444.08 ± 71.44
294.14 ± 69.27a
408.50 ± 66.85b
312.58 ± 75.55
360.00 ± 57.19c
405.81 ± 63.36b
406.16 ± 56.39b
CAT (U/mg protein)
298.02 ± 21.30
174.22 ± 14.52a
287.34 ± 22.71b
196.35 ± 18.90b
209.42 ± 23.00b
212.56 ± 20.66b
274.30 ± 21.94b
SOD (U/mg protein)
415.00 ± 33.20
197.38 ± 36.55a
385.52 ± 32.11b
222.44 ± 36.40
356.78 ± 37.80b
379.91 ± 38.92b
364.82 ± 40.24b
GSH-Px (U/mg protein)
658 ± 89
462 ± 92a
711 ± 101b
555 ± 74c
596 ± 94b
623 ± 78b
539 ± 79b
MDA (nmol/mg protein)
8.77 ± 1.03
14.91 ± 1.44a
8.05 ± 1.11b
12.50 ± 1.48b
10.87 ± 1.61b
9.22 ± 1.31b
8.99 ± 1.40b
Values are means ± SD for 10 rats in each group. N group: normal control; D group: diabetes group; N + G group: normal control plus GBE; D + LG group: diabetes plus low GBE treatment; D + MG group: diabetes plus middle GBE treatment; D + HG group: diabetes plus high GBE treatment; D + GLI group: diabetes plus glibenclamide treatment.
aIndicates statistical significance of compared to N group; b compared to D group.
c compared to D group.